by Hanna | Feb 21, 2024 | Blog Post
In recent months, the Federal Trade Commission (FTC) and Department of Justice (DOJ) have pursued an increasingly aggressive new approach towards mergers and acquisitions (M&A). Taken together, the Agencies’ recently finalized Merger Guidelines and proposed...
by Hanna | Feb 13, 2024 | Blog Post
In a recent commentary for Law 360, biopharma expert Michael Kinch and economists Jee-Yonn Lehmann and Frederico Mantovanelli rightly point out that biopharmaceutical mergers and acquisitions (M&A) and other collaborations play an important role in promoting...
by Hanna | Feb 7, 2024 | Blog Post
Life sciences companies of all sizes face extended time and cost pressures as they work to bring new medicines to patients, as the average cost of research and development (R&D) can exceed $2.8 billion, and it can take more than 10-15 years to bring a new therapy...
by Hanna | Jan 30, 2024 | Blog Post
The Hart-Scott-Rodino (HSR) Act requires companies to report information to the Federal Trade Commission (FTC) and Department of Justice (DOJ) before a planned merger or acquisition (M&A). Under the HSR Act, the agencies enforce premerger reporting requirements...
by Hanna | Jan 10, 2024 | Blog Post, PULSE Partner
PULSE had a conversation with Joan Koerber-Walker, president and CEO of AZBio, which recently celebrated 20 years of supporting the growth of Arizona’s life science industry. Joan, who has led AZBio since 2011, has a vested interest in making Arizona a place where...
by Hanna | Jan 3, 2024 | Blog Post
Thousands of life sciences companies from across the U.S. compete every day to bring the next generation of treatments and cures to market. Within this ecosystem, pharmaceutical manufacturers play a key role in developing new therapies and cures. By mobilizing their...
